EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Market is segmented By Treatment (EGFR-TKI Inhibitors, Immunotherapy), By Stages of the Disease (Early-stage NSCLC, Metastatic NSCLC), By Therapy Approvals (First-line Treatments, Second-line Treatments), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa).The report offers the value (in USD billion) for the above-mentioned segments.

EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Market Leaders

  • AstraZeneca
  • Janssen Pharmaceuticals
  • Pfizer
  • Roche
  • Novartis
*Disclaimer: Major players are listed in no particular order.

EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Market - Company List

  • AstraZeneca
  • Janssen Pharmaceuticals
  • Pfizer
  • Roche
  • Novartis
  • Cullinan Oncology
  • Bridge Biotherapeutics
  • ORIC Pharmaceuticals
  • BeiGene
  • Dizal Pharmaceuticals
  • Merck & Co.
  • Bristol-Myers Squibb

EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Market Report Snapshots

Buy Now